OKYO
OKYO Pharma Limited
Biotechnology
Market Cap$66M
5Y Perf.-20.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OKYO vs ALDX vs HALO vs TARS
Revenue, margins, valuation, and 5-year total return — side by side.
ALDX
Aldeyra Therapeutics, Inc.
Biotechnology
Market Cap$104M
5Y Perf.-44.0%
HALO
Halozyme Therapeutics, Inc.
Biotechnology
Market Cap$7.55B
5Y Perf.+39.5%
TARS
Tarsus Pharmaceuticals, Inc.
Biotechnology
Market Cap$2.63B
5Y Perf.+345.2%
OKYO vs ALDX vs HALO vs TARS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OKYO | ALDX | HALO | TARS |
|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $66M | $104M | $7.55B | $2.63B |
| Revenue (TTM) | $0.00 | $0.00 | $1.40B | $535M |
| Net Income (TTM) | $-5M | $-43M | $317M | $-48M |
| Gross Margin | — | — | 81.9% | 90.4% |
| Operating Margin | — | — | 58.4% | -9.5% |
| Forward P/E | — | 24.7x | 8.0x | — |
| Total Debt | $0.00 | $15M | $0.00 | $94M |
| Cash & Equiv. | $2M | $55M | $134M | $184M |
OKYO vs ALDX vs HALO vs TARS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OKYO
ALDX
HALO
TARS
| Stock | May 22 | May 26 | Return |
|---|---|---|---|
| OKYO Pharma Limited (OKYO) | 100 | 79.5 | -20.5% |
| Aldeyra Therapeutic… (ALDX) | 100 | 56.0 | -44.0% |
| Halozyme Therapeuti… (HALO) | 100 | 139.5 | +39.5% |
| Tarsus Pharmaceutic… (TARS) | 100 | 445.2 | +345.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OKYO vs ALDX vs HALO vs TARS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: HALO leads in 4 of 7 categories, making it the strongest pick for valuation and capital efficiency and profitability and margin quality. Tarsus Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
OKYO
OKYO Pharma Limited
The Specific-Use Pick
OKYO plays a supporting role in this comparison — it may shine differently against other peers.
Best for: healthcare exposure
ALDX
Aldeyra Therapeutics, Inc.
The Secondary Option
ALDX lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
HALO
Halozyme Therapeutics, Inc.
The Income Pick
HALO carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 0.51
- 5.6% 10Y total return vs TARS's 197.4%
- Lower volatility, beta 0.51, current ratio 4.66x
- Beta 0.51, current ratio 4.66x
Best for: income & stability and long-term compounding
TARS
Tarsus Pharmaceuticals, Inc.
The Growth Play
TARS is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 146.7%, EPS growth 48.2%, 3Y rev CAGR 159.5%
- 146.7% revenue growth vs OKYO's -11K%
- +29.8% vs ALDX's -19.9%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | TARS | 146.7% revenue growth vs OKYO's -11K% |
| Value | HALO | Better valuation composite |
| Quality / Margins | HALO | 22.7% margin vs OKYO's -23.9% |
| Stability / Safety | HALO | Beta 0.51 vs ALDX's 1.28 |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | TARS | +29.8% vs ALDX's -19.9% |
| Efficiency (ROA) | HALO | 12.5% ROA vs OKYO's -128.4% |
OKYO vs ALDX vs HALO vs TARS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
FY 2025
OKYO vs ALDX vs HALO vs TARS — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLHALOLAGGINGALDX
Who Leads Where
HALO leads in 4 of 6 categories
TARS leads 1 • OKYO leads 0 • ALDX leads 0
Explore the data ↓ALDXAldeyra Therapeutics,…
0leads
OKYOOKYO Pharma Limited
0leads
TARSTarsus Pharmaceutical…
1leads
HALOHalozyme Therapeutics…
4leads
6 Total Categories
CATEGORYLEADERvs TARSvs OKYOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
HALO3/6
Valuation MetricsMultiples, price ratios, and targets
HALO2/4
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
HALO8/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TARS4/6
Risk & VolatilityBeta, volatility, and downside exposure
HALO2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
HALO leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
HALO and ALDX operate at a comparable scale, with $1.4B and $0 in trailing revenue. HALO is the more profitable business, keeping 22.7% of every revenue dollar as net income compared to TARS's -9.0%. On growth, TARS holds the edge at +106.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OKYOOKYO Pharma Limit… | ALDXAldeyra Therapeut… | HALOHalozyme Therapeu… | TARSTarsus Pharmaceut… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $1.4B | $535M |
| EBITDAEarnings before interest/tax | -$4M | -$45M | $945M | -$49M |
| Net IncomeAfter-tax profit | -$5M | -$43M | $317M | -$48M |
| Free Cash FlowCash after capex | -$2M | -$40M | $645M | -$32M |
| Gross MarginGross profit ÷ Revenue | — | — | +81.9% | +90.4% |
| Operating MarginEBIT ÷ Revenue | — | — | +58.4% | -9.5% |
| Net MarginNet income ÷ Revenue | — | — | +22.7% | -9.0% |
| FCF MarginFCF ÷ Revenue | — | — | +46.2% | -5.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +51.6% | +106.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +83.3% | +48.0% | -2.1% | +75.0% |
HALO leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
HALO leads this category, winning 2 of 4 comparable metrics.
Valuation Metrics
| Metric | OKYOOKYO Pharma Limit… | ALDXAldeyra Therapeut… | HALOHalozyme Therapeu… | TARSTarsus Pharmaceut… |
|---|---|---|---|---|
| Market CapShares × price | $66M | $104M | $7.6B | $2.6B |
| Enterprise ValueMkt cap + debt − cash | $65M | $65M | $7.4B | $2.5B |
| Trailing P/EPrice ÷ TTM EPS | -13.58x | -1.84x | 25.05x | -38.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 24.71x | 7.96x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | 1.09x | — |
| EV / EBITDAEnterprise value multiple | — | — | 8.20x | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 5.41x | 5.83x |
| Price / BookPrice ÷ Book value/share | — | 1.45x | 162.76x | 7.45x |
| Price / FCFMarket cap ÷ FCF | — | — | 11.72x | — |
HALO leads this category, winning 2 of 4 comparable metrics.
Profitability & Efficiency
HALO leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
HALO delivers a 6.5% return on equity — every $100 of shareholder capital generates $6 in annual profit, vs $-88 for ALDX. ALDX carries lower financial leverage with a 0.22x debt-to-equity ratio, signaling a more conservative balance sheet compared to TARS's 0.27x. On the Piotroski fundamental quality scale (0–9), HALO scores 5/9 vs ALDX's 1/9, reflecting solid financial health.
| Metric | OKYOOKYO Pharma Limit… | ALDXAldeyra Therapeut… | HALOHalozyme Therapeu… | TARSTarsus Pharmaceut… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -87.7% | +6.5% | -14.2% |
| ROA (TTM)Return on assets | -128.4% | -55.5% | +12.5% | -8.9% |
| ROICReturn on invested capital | — | -3.7% | +73.4% | -23.4% |
| ROCEReturn on capital employed | — | -56.7% | +38.2% | -19.6% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 1 | 5 | 5 |
| Debt / EquityFinancial leverage | — | 0.22x | — | 0.27x |
| Net DebtTotal debt minus cash | -$2M | -$39M | -$134M | -$90M |
| Cash & Equiv.Liquid assets | $2M | $55M | $134M | $184M |
| Total DebtShort + long-term debt | $0 | $15M | $0 | $94M |
| Interest CoverageEBIT ÷ Interest expense | -8.03x | -21.72x | 46.08x | -18.76x |
HALO leads this category, winning 8 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TARS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in TARS five years ago would be worth $21,931 today (with dividends reinvested), compared to $1,437 for ALDX. Over the past 12 months, TARS leads with a +29.8% total return vs ALDX's -19.9%. The 3-year compound annual growth rate (CAGR) favors TARS at 57.8% vs ALDX's -45.5% — a key indicator of consistent wealth creation.
| Metric | OKYOOKYO Pharma Limit… | ALDXAldeyra Therapeut… | HALOHalozyme Therapeu… | TARSTarsus Pharmaceut… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -26.9% | -63.0% | -8.8% | -24.2% |
| 1-Year ReturnPast 12 months | +10.1% | -19.9% | -5.3% | +29.8% |
| 3-Year ReturnCumulative with dividends | -23.5% | -83.8% | +111.8% | +292.6% |
| 5-Year ReturnCumulative with dividends | -55.0% | -85.6% | +39.1% | +119.3% |
| 10-Year ReturnCumulative with dividends | -55.0% | -72.1% | +559.7% | +197.4% |
| CAGR (3Y)Annualised 3-year return | -8.5% | -45.5% | +28.4% | +57.8% |
TARS leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
HALO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
HALO is the less volatile stock with a 0.51 beta — it tends to amplify market swings less than ALDX's 1.28 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. HALO currently trades 78.0% from its 52-week high vs ALDX's 28.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OKYOOKYO Pharma Limit… | ALDXAldeyra Therapeut… | HALOHalozyme Therapeu… | TARSTarsus Pharmaceut… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.98x | 1.28x | 0.51x | 0.66x |
| 52-Week HighHighest price in past year | $3.35 | $6.18 | $82.22 | $85.25 |
| 52-Week LowLowest price in past year | $1.32 | $1.07 | $47.50 | $38.51 |
| % of 52W HighCurrent price vs 52-week peak | +48.7% | +28.0% | +78.0% | +71.8% |
| RSI (14)Momentum oscillator 0–100 | 50.2 | 42.5 | 47.7 | 44.2 |
| Avg Volume (50D)Average daily shares traded | 93K | 3.6M | 1.4M | 500K |
HALO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: ALDX as "Buy", HALO as "Buy", TARS as "Buy". Consensus price targets imply 459.0% upside for ALDX (target: $10) vs 17.9% for HALO (target: $76).
| Metric | OKYOOKYO Pharma Limit… | ALDXAldeyra Therapeut… | HALOHalozyme Therapeu… | TARSTarsus Pharmaceut… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | — | $9.67 | $75.60 | $89.33 |
| # AnalystsCovering analysts | — | 19 | 27 | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | 1 | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +4.5% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
HALO leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). TARS leads in 1 (Total Returns).
Best OverallHalozyme Therapeutics, Inc. (HALO)Leads 4 of 6 categories
Loading custom metrics...
OKYO vs ALDX vs HALO vs TARS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is OKYO or ALDX or HALO or TARS a better buy right now?
For growth investors, Tarsus Pharmaceuticals, Inc.
(TARS) is the stronger pick with 146. 7% revenue growth year-over-year, versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). Halozyme Therapeutics, Inc. (HALO) offers the better valuation at 25. 0x trailing P/E (8. 0x forward), making it the more compelling value choice. Analysts rate Aldeyra Therapeutics, Inc. (ALDX) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OKYO or ALDX or HALO or TARS?
On forward P/E, Halozyme Therapeutics, Inc.
is actually cheaper at 8. 0x.
03Which is the better long-term investment — OKYO or ALDX or HALO or TARS?
Over the past 5 years, Tarsus Pharmaceuticals, Inc.
(TARS) delivered a total return of +119. 3%, compared to -85. 6% for Aldeyra Therapeutics, Inc. (ALDX). Over 10 years, the gap is even starker: HALO returned +559. 7% versus ALDX's -72. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OKYO or ALDX or HALO or TARS?
By beta (market sensitivity over 5 years), Halozyme Therapeutics, Inc.
(HALO) is the lower-risk stock at 0. 51β versus Aldeyra Therapeutics, Inc. 's 1. 28β — meaning ALDX is approximately 150% more volatile than HALO relative to the S&P 500. On balance sheet safety, Aldeyra Therapeutics, Inc. (ALDX) carries a lower debt/equity ratio of 22% versus 27% for Tarsus Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — OKYO or ALDX or HALO or TARS?
By revenue growth (latest reported year), Tarsus Pharmaceuticals, Inc.
(TARS) is pulling ahead at 146. 7% versus 37. 6% for Halozyme Therapeutics, Inc. (HALO). On earnings-per-share growth, the picture is similar: Tarsus Pharmaceuticals, Inc. grew EPS 48. 2% year-over-year, compared to -46. 9% for Aldeyra Therapeutics, Inc.. Over a 3-year CAGR, TARS leads at 159. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OKYO or ALDX or HALO or TARS?
Halozyme Therapeutics, Inc.
(HALO) is the more profitable company, earning 22. 7% net margin versus -14. 7% for Tarsus Pharmaceuticals, Inc. — meaning it keeps 22. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -15. 7% for TARS. At the gross margin level — before operating expenses — TARS leads at 93. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OKYO or ALDX or HALO or TARS more undervalued right now?
On forward earnings alone, Halozyme Therapeutics, Inc.
(HALO) trades at 8. 0x forward P/E versus 24. 7x for Aldeyra Therapeutics, Inc. — 16. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALDX: 459. 0% to $9. 67.
08Which pays a better dividend — OKYO or ALDX or HALO or TARS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
09Is OKYO or ALDX or HALO or TARS better for a retirement portfolio?
For long-horizon retirement investors, Halozyme Therapeutics, Inc.
(HALO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 51), +559. 7% 10Y return). Both have compounded well over 10 years (HALO: +559. 7%, ALDX: -72. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OKYO and ALDX and HALO and TARS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: OKYO is a small-cap quality compounder stock; ALDX is a small-cap quality compounder stock; HALO is a small-cap high-growth stock; TARS is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.